$120.85$150.99
Prepare to embark on a sensory journey with the Bosco Apple, a fruit that transcends the ordinary and promises an unparalleled taste experience. These apples are nothing short of nature’s masterpiece, celebrated for their distinctive blend of flavors and their captivating visual allure.
Availability: In Stock
Subscribe to out newsletter today to receive latest news administrate cost effective for tactical data.
₹2559
INTRODUCTION PEG GRAFEEL INJECTION(PFS) contains Pegfilgrastim which belongs to the group of medicines called Colony stimulating factors. It is used to prevent the destruction of white blood cells (WBC) in blood that is caused due to chemotherapy. It reduces the occurrence of neutropenia (low...
PEG GRAFEEL INJECTION(PFS) contains Pegfilgrastim which belongs to the group of medicines called Colony stimulating factors. It is used to prevent the destruction of white blood cells (WBC) in blood that is caused due to chemotherapy. It reduces the occurrence of neutropenia (low WBC count in blood) and febrile neutropenia (low WBC count in blood with fever) among patients receiving chemotherapy.
Talk to your doctor before receiving PEG GRAFEEL INJECTION(PFS) if you have any problems in your lungs or with blood circulation. You must also inform your doctor if you are allergic to Pegfilgrastim or filgrastim or have breast cancer, lung cancer or anemia as a precaution
Inform your doctor before receiving PEG GRAFEEL INJECTION(PFS) if you are pregnant or breastfeeding. The most common side effects of receiving PEG GRAFEEL INJECTION(PFS) are bone pain, nausea, headache, skin rashes, pain, redness and discomfort at the site of injection and muscle pain. Inform your doctor if any of these side effect troubles you.
PEG GRAFEEL INJECTION(PFS) works by stimulating the bone marrow to produce more white blood cells. It also enhances the survival of the white blood cells by protecting it against the harmful effects of chemotherapy. This reduces the risk of neutropenia and its associated complications (such as fever, flu, and risk of infections) among patients receiving chemotherapy.
PEG GRAFEEL INJECTION(PFS) should be administered beneath the skin (subcutaneously). It is either administered to you by a doctor or a nurse or can be self-administered if instructed by the doctor. Carefully follow the instructions given by your doctor in case of self-administration.
Your doctor will decide the correct dose and duration of therapy for you depending upon your age, body weight and disease condition.
Inform your doctor immediately if you experience any of the following side effects:
Rest and relax. Keep yourself hydrated by drinking plenty of fluids such as water or electrolytes. Applying a pain-relieving balm on your forehead can be beneficial. Consult your doctor if your headache worsens.
Place an ice pack on the injected site. Do not move the affected area frequently. If the symptom worsens, consult your doctor.
Stick to simple meals and avoid oil rich or spicy foods. Consult your doctor if nausea worsens.
PEG GRAFEEL INJECTION(PFS) is not tested in pregnant women. Therefore, consult your doctor before this medicine is administered to you.
PEG GRAFEEL INJECTION(PFS) should be used in breast-feeding women only if considered necessary by the physician. Kindly consult your doctor before receiving it.
Do not drive or operate any machines if your ability is affected by PEG GRAFEEL INJECTION(PFS).
Avoid consumption of alcohol before receiving PEG GRAFEEL INJECTION(PFS) to avoid unwanted reactions.
PEG GRAFEEL INJECTION(PFS) should be used with caution in patients with kidney diseases. Therefore, consult your doctor before receiving it.
Talk to your doctor before receiving PEG GRAFEEL INJECTION(PFS) if you are allergic to Pegfilgrastim or filgrastim.
PEG GRAFEEL INJECTION(PFS) should be used with caution in patients with lung problems (such as recent, serious lung infection (pneumonia), pulmonary oedema (fluid build-up in lungs) or lung inflammation or an abnormal chest x-ray). Therefore, consult your doctor before receiving it.
PEG GRAFEEL INJECTION(PFS) is not suitable for use in children and adolescents (aged below 18 years). Therefore, consult your doctor before receiving it.
PEG GRAFEEL INJECTION(PFS) should be used with caution in elderly patients (aged 65 years or older). Therefore, consult your doctor before receiving it.
Before receiving PEG GRAFEEL INJECTION(PFS), inform your doctor if you:
A. Drug - Drug interactions:
Before receiving PEG GRAFEEL INJECTION(PFS) inform your doctor if you are taking any other prescription, non-prescription and over-the-counter medicines.
Overdosage:
PEG GRAFEEL INJECTION(PFS) will be administered to you only by a doctor or a nurse in a hospital, and so it is unlikely to receive an overdose. However, consult your doctor or nurse if you experience any unusual symptoms.
| Drug | : | Pegfilgrastim |
| Pharmacological Category | : | Colony Stimulating Factor |
| Therapeutic Indication | : | Prevents Neutropenia |
| Dosage Forms | : | Injection, Pre-Filled Syringe |
Q: What is the use of PEG GRAFEEL INJECTION(PFS)?
A: PEG GRAFEEL INJECTION(PFS) is used to prevent the destruction of white blood cells (WBC) in blood that is caused due to chemotherapy. It reduces the occurrence of neutropenia (low WBC count in blood) and febrile neutropenia (low WBC count in blood with fever) among patients receiving chemotherapy
Q: How PEG GRAFEEL INJECTION(PFS) works?
A: PEG GRAFEEL INJECTION(PFS) works by stimulating the bone marrow to produce more white blood cells. It also enhances the survival of the white blood cells by protecting it against the harmful effects of chemotherapy.
Q: When is PEG GRAFEEL INJECTION(PFS) given?
A: PEG GRAFEEL INJECTION(PFS) is given after 24 hours of your last dose of chemotherapy at the end of each chemotherapy cycle.
Q: Where PEG GRAFEEL INJECTION(PFS) should be administered?
A: PEG GRAFEEL INJECTION(PFS) should be administered beneath the skin (subcutaneously). It is either administered to you by a doctor or a nurse or can be self-administered if instructed by the doctor.
Q: What are the side effects of PEG GRAFEEL INJECTION(PFS)?
A: The most common side effects of receiving PEG GRAFEEL INJECTION(PFS) are bone pain, nausea, headache, skin rashes, pain, redness and discomfort at the site of injection and muscle pain. Inform your doctor if any of these side effect troubles you.
Q: Can PEG GRAFEEL INJECTION(PFS) be given during pregnancy?
A: PEG GRAFEEL INJECTION(PFS) is not tested in pregnant women. Therefore, consult your doctor before this medicine is administered to you.
Q: Will PEG GRAFEEL INJECTION(PFS) reduce the effects of chemotherapy?
A: PEG GRAFEEL INJECTION(PFS) will only prevent from the harmful effects of chemotherapy. It does not reduce the effectiveness of chemotherapy.
Q: Is PEG GRAFEEL INJECTION(PFS) effective?
A: Yes. PEG GRAFEEL INJECTION(PFS) effectively prevents the risk of low WBC count among patients receiving chemotherapy.
1. Goodman & Gilman’s: The Pharmacological Basics of Therapeutics. Inflammation, Immunomodulation and Hematopoiesis. 12th Edition. Page – 1075.
2. Savannah D. Parker; Nafisa King; Tibb F. Jacobs. Pegfilgrastim. StatPearls. NIH. National Library of Medicine. National Center for Biotechnology Information. PMC. PubMed Central. August 2022. [Accessed on 14th February 2023]. https://www.ncbi.nlm.nih.gov/books/NBK532893/
3. Zhisheng Zhang, Huan Li, Jiacheng Zhang, Xuan Ye, Hongyue Liu, Qing Zhai, Bo Yu, Qiong Du. Effect of 3 mg versus 6 mg pegfilgrastim on the prevention of febrile neutropenia in breast cancer patients receiving docetaxel and cyclophosphamide: a retrospective study. NIH. National Library of Medicine. National Center for Biotechnology Information. PMC. Pubmed.gov. May 2021. [Accessed on 14th February 2023]. https://pubmed.ncbi.nlm.nih.gov/33977742/
4. Amgen Europe B.V. Neulasta 6 mg solution for injection pegfilgrastim. Electronics Medicines Compendium. [Revised in June 2021]. [Accessed on 14th February 2023]. https://www.medicines.org.uk/emc/files/pil.10091.pdf
5. Amgen Inc. NEULASTA® (pegfilgrastim) injection, for subcutaneous use. U.S. Food and Drug Administration. [Revised in April 2019]. [Accessed on 14th February 2023]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125031s198lbl.pdf
Written By Srilekha. R, B.Pharm
Last updated on 16 Feb 2023 | 04:42 PM(IST)